Free Trial
NASDAQ:QNCX

Quince Therapeutics (QNCX) Stock Price, News & Analysis

Quince Therapeutics logo
$31.73 0.00 (0.00%)
As of 10/13/2026

About Quince Therapeutics Stock (NASDAQ:QNCX)

Key Stats

Today's Range
$31.73
▼
$31.73
50-Day Range
$26.72
▼
$32.01
52-Week Range
$15.10
▼
$909.98
Volume
N/A
Average Volume
31,090 shs
Market Capitalization
$32.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$189.88
Consensus Rating
Moderate Buy

Company Overview

Quince Therapeutics is a biotechnology company focused on developing treatments for rare diseases. Its principal program has been EryDex, an investigational therapy designed to deliver dexamethasone sodium phosphate inside a patient’s own red blood cells.

The company developed EryDex for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological and immune-system problems. The treatment uses a process intended to load the drug into red blood cells for gradual release. Quince’s program followed its 2023 combination with EryDel, the company that developed the EryDex technology.

EryDex was evaluated in a Phase 3 clinical trial, which did not meet its primary efficacy endpoint. Quince is headquartered in the United States; its work on EryDex grew out of technology developed by EryDel in Europe.

AI Generated. May Contain Errors.

Quince Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

QNCX MarketRank™: 
2.119078947365 of 5 stars

Quince Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 647th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Quince Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 2 strong buy ratings, 7 buy ratings, 3 hold ratings, and 2 sell ratings.

  • Upside Potential

    Quince Therapeutics has a consensus price target of $189.88, representing about 498.4% upside from its current price of $31.73.

  • Amount of Analyst Coverage

    Quince Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Quince Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Quince Therapeutics are expected to grow in the coming year, from ($8.39) to ($3.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Quince Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for QNCX.
  • Dividend Yield

    Quince Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Quince Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Quince Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.60% of the stock of Quince Therapeutics is held by insiders.

  • Percentage Held by Institutions

    30.75% of the stock of Quince Therapeutics is held by institutions.

  • Read more about Quince Therapeutics' insider trading history.
Receive QNCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QNCX Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

QNCX Stock Analysis - Frequently Asked Questions

Quince Therapeutics' stock was trading at $670.00 on January 1st, 2026. Since then, QNCX stock has decreased by 95.3% and is now trading at $31.73.

Quince Therapeutics, Inc. (NASDAQ:QNCX) released its quarterly earnings data on Friday, August, 14th. The company reported ($12.31) EPS for the quarter, beating analysts' consensus estimates of ($28.02) by $15.71.

Quince Therapeutics shares reverse split on the morning of Tuesday, June 30th 2026.The 1-20 reverse split was announced on Friday, June 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Quince Therapeutics (QNCX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,412,000 shares at a price of $16.00-$18.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include NVIDIA (NVDA), Cassava Sciences (FLNA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Pfizer (PFE) and Ford Motor (F).

Company Calendar

Last Earnings
8/14/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:QNCX
Previous Symbol
NASDAQ:CRTX
CIK
1662774
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$1,000.00
Low Price Target
$68.00
Potential Upside/Downside
+498.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($156.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$83.98 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-133.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.52
Quick Ratio
14.52

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($128.18) per share
Price / Book
-0.25

Miscellaneous

Outstanding Shares
1,017,000
Free Float
960,000
Market Cap
$32.27 million
Optionable
No Data
Beta
1.33
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:QNCX) was last updated on 10/13/2026 by MarketBeat.com Staff.
From Our Partners